Can a rare immune cell offer the key to slowing down senescence? A Bay Area startup looks to find out

For years, scientists have looked to curb aging and chronic diseases by clearing defunct cells with irreparable damage, also known as senescent cells. Drugmakers like Bristol Myers Squibb and Unity Biotechnology have toiled over senolytics to kill the stubborn cells. So when Robin Mansukhani was told it could be done...

Click to view original post